KKKentaro Kohagura

Kentaro Kohagura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kentaro Kohagura has a total of 304 co-authors. Here are the top co-authors by number of shared publications:

  • Yusuke Ohya

    Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus Graduate School of Medicine, Nephrology and Neurology, Nishihara-cho

    28 shared publications
  • Kunitoshi Iseki

    Okinawa Heart and Renal Association and Clinical Research Support Center Nakamura Clinic Okinawa Japan

    12 shared publications
  • Ryo Zamami

    Department of Cardiovascular Medicine, Nephrology and Neurology Faculty of Medicine, University of the Ryukyus, Okinawa, Japan

    12 shared publications
  • Masako Kochi

    Department of nephrology, Tomishiro Chuo Hospital, Tomigusuku

    11 shared publications
  • Kunitoshi Iseki

    Nakamura Clinic, Urasoe, Japan

    10 shared publications
  • Masanobu Yamazato

    Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus Graduate School of Medicine, Nephrology and Neurology, Nishihara-cho

    9 shared publications

Latest Publications

  • Open Access

    Cancer Risk in Haemodialysis Patients Compared With That in the General Population: A Multicenter Questionnaire‐Based Study in Okinawa, Japan

    byĀ Yoko Arakawa, Yuriko Ishida, Akira Higa, Takeshi Tana, Takuhiro Moromizato, Kentaro Kohagura, Kunitoshi Iseki

    Aim: Dialysis patients face a heightened risk of cancer, particularly kidney cancer. The global aging of dialysis patients suggests that managing cancer may become a critical factor in future healthcare. Given that the chronic uremic state is a cancer risk factor, dialysis patients may face an elevated risk for all cancers. However, the epidemiology of nonkidney cancers, such as colorectal cancer, remains to be fully elucidated. Methods: This was a retrospective cohort study targeting 74 dialysis facilities in Okinawa Prefecture, Japan. The subjects were patients who received dialysis for a minimum of 90 days between 2015 and 2019 and were diagnosed with cancer after initiating dialysis during this period. The cancer incidence ratio for the study population (21 655 person‐years) was then compared with that of the general Okinawan population using standardized incidence ratios. Results: A total of 404 cancer cases were collected from 56 facilities (76%). The standardized incidence ratios for all cancers was 1.36, with the risk of kidney cancer increasing with longer dialysis vintage. Patients with a dialysis vintage of less than 2 years showed an increased risk of colorectal and lung cancer. The risk of breast cancer was similar to that of the general population. Conclusion: The present study revealed that not all cancer risks were increased among patients receiving haemodialysis. Screening for colorectal and lung cancer in the first 2 years after commencement of dialysis may be important. Further research is needed to determine the efficacy of this approach for patients receiving dialysis.


  • Impact of Lupus on All‐Cause, Cardiovascular, and Infection‐Related Mortality Among Dialysis Patients: Okinawa Dialysis Study Registry

    byĀ Nanako Oshiro, Yukiko Hasuike, Kentaro Kohagura, Kunitoshi Iseki

    Introduction: Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE) and can lead to end‐stage kidney disease (ESKD). We aimed to assess the relative mortality risk associated with SLE among dialysis patients. Methods: This retrospective longitudinal cohort study included all dialysis patients in the Okinawa Dialysis Study 30 registry. Cox proportional hazard models were performed to assess mortality. Results: Of 5246 patients, 111 had ESKD secondary to SLE. Compared with ESKD patients secondary to other causes, those with SLE had significantly higher risk of death (HR 2.55, 95% CI 1.81–3.47, p < 0.0001), cardiovascular death (HR 1.94, 95% CI 1.13–3.33, p = 0.0158), and infection death (HR 4.21, 95% CI 2.40–7.37, p < 0.0001) after adjusting for age, era of dialysis initiation, and sex. Conclusion: SLE may be independently associated with an increased risk of death in dialysis patients.

  • Sustained eGFR improvement after dapagliflozin in a patient with antiretroviral therapy-related chronic kidney disease

    byĀ Hirotaka Arae, Shinichi Hoshino, Nao Moromi, Kouichi Tokumine, Kentaro Kohagura

    Chronic kidney disease (CKD) is an emerging concern in the aging population of people living with HIV, especially in those with history of nephrotoxic antiretroviral therapy. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown renoprotective effects in various clinical settings, but their utility in patients with antiretroviral-induced kidney impairment remains unexplored. We report the case of a 59-year-old man with well-controlled HIV infection who developed progressive decline in estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) over 15 years of taking antiretroviral therapy (ΔeGFR - 2.3 mL/min/1.73 m2 per year), including 8 years of tenofovir disoproxil fumarate (TDF) intake. After discontinuation of TDF and its successor drug, the eGFR stabilized at approximately 52 for approximately 4 years. The SGLT2 inhibitor dapagliflozin was started to prevent renal decline. Subsequently, the eGFR increased to 57.3 after 3 months and 60.2 after 6 months, then was maintained at approximately 57 thereafter. After dapagliflozin initiation, the overall eGFR slope was + 1.2 mL/min/1.73 m2 per year. To the best of our knowledge, this was the first report demonstrating improvement in eGFR slope after SGLT2 inhibitor use in a patient with antiretroviral-associated renal impairment. This highlighted the potential role of SGLT2 inhibitors in mitigating CKD progression in people living with HIV.


  • Open Access

    Efficacy and safety of early administration of remdesivir in hemodialysis patients with COVID-19: A case report and literature review

    byĀ Nanako Oshiro, Takeshi Kinjo, Daigo Aharen, Yuki Kudo, Eisuke Katsuren, Kumiko Omine, Takuto Nakamura, Ryo Zamami, Akio Ishida, Kazuya Miyagi, et al.

    Rationale: Although the mortality of severe coronavirus disease 2019 (COVID-19) has decreased after the emergence of the Omicron variant, it remains high in patients on hemodialysis (HD). Remdesivir (RDV) is considered as the first line drug for hospitalized COVID-19 patients, however the evidence regarding the usage in HD patients is lacking because clinical trials of RDV have excluded HD patients for safety reasons. Thus, accumulation of knowledge on the regimen, efficacy, and tolerability of RDV in HD patients is important. Patient concerns: A nosocomial COVID-19 cluster was occurred from August 31 to October 12 in 2021 when the Delta variant was predominant. During the cluster, 11 health-care workers and 20 inpatients including 7 HD patients were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnoses: The diagnosis of COVID-19 was confirmed by the real-time polymerase chain reaction (PCR) for SARS-CoV-2. Interventions: RDV was initiated within 16 hours after the onset of fever (≄ 37.4°C) or positive PCR result in all HD patients, and continued at 100 mg/day intravenously once daily for either consecutive 5 or 10 days. Outcomes: All patients fully recovered within 2 weeks and did not develop severe COVID-19. Two patients experienced mild liver dysfunction, but it was temporary and remitted spontaneously even continuing RDV treatment. Discontinuation of RDV therapy due to adverse events was not required in any patients. Lessons: Present cases indicated early intervention with RDV may contribute the favorable outcome and daily administration of RDV for up to 10 days was well tolerated even in HD patients. Literature review showed no previous article reported the efficacy and safety of such earlier and longer administration of remdesivir as in the present cases, therefore this report is informative for clinicians to consider the usage of RDV in HD patients.


  • Open Access

    Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure–dependent renal damage

    byĀ Kentaro Kohagura, Ryo Zamami, Nanako Oshiro, Yuki Shinzato, Noriko Uesugi

    Hypertension, aging, and other factors are associated with arteriosclerosis and arteriolosclerosis, primary morphological features of nephrosclerosis. Although such pathological changes are not invariably linked with renal decline but are prevalent across chronic kidney disease (CKD), understanding kidney damage progression is more pragmatic than precisely diagnosing nephrosclerosis itself. Hyalinosis and medial thickening of the afferent arteriole, along with intimal thickening of small arteries, can disrupt the autoregulatory system, jeopardizing glomerular perfusion pressure given systemic blood pressure (BP) fluctuations. Consequently, such vascular lesions cause glomerular damage by inducing glomerular hypertension and ischemia at the single nephron level. Thus, the interaction between systemic BP and afferent arteriolopathy markedly influences BP-dependent renal damage progression in nephrosclerosis. Both dilated and narrowed types of afferent arteriolopathy coexist throughout the kidney, with varying proportions among patients. Therefore, optimizing antihypertensive therapy to target either glomerular hypertension or ischemia is imperative. In recent years, clinical trials have indicated that combining renin–angiotensin system inhibitors (RASis) and sodium–glucose transporter 2 inhibitors (SGLT2is) is superior to using RASis alone in slowing renal function decline, despite comparable reductions in albuminuria. The superior efficacy of SGLT2is may arise from their beneficial effects on both glomerular hypertension and renal ischemia. A comprehensive understanding of the interaction between systemic BP and heterogeneous afferent arteriolopathy is pivotal for optimizing therapy and mitigating renal decline in patients with CKD of any etiology. Therefore, in this comprehensive review, we explore the role of afferent arteriolopathy in BP-dependent renal damage.


  • Open Access

    The Association of Smoking and Hyperuricemia with Renal Arteriolosclerosis in IgA Nephropathy

    byĀ Yuki Shinzato, Ryo Zamami, Nanako Oshiro, Takuto Nakamura, Akio Ishida, Yusuke Ohya, Kentaro Kohagura

    The combination effects of smoking (SMK) and hyperuricemia (HU) on renal arteriolosclerosis in patients with IgA nephropathy remain unknown. We examined the cross-sectional association between smoking (current or former) and renal arteriolar hyalinosis and wall thickening with or without HU [uric acid (UA) level ≄ 7 and ≄5 mg/dL in men and women] in 87 patients with IgA nephropathy who underwent renal biopsy. Arteriolar hyalinosis and wall thickening were assessed by the semiquantitative grading of arterioles. The SMK/HU subgroup showed the highest indices for hyalinosis and wall thickening, followed by the non-SMK/HU, SMK/non-HU, and non-SMK/non-HU subgroups. Multiple logistic analysis showed that SMK/HU, but not SMK/non-HU, was significantly associated with an increased risk of higher-grade renal arteriolar wall thickening. However, this did not occur with hyalinosis compared to non-SMK/non-HU. The adjusted odds ratio (95% confidence interval, p value) for SMK/HU was 12.8 (1.36–119, p < 0.05) for wall thickening. An association between SMK and renal arteriolar wall thickening might be prevalent only among patients with HU and in patients with IgA nephropathy. Further prospective studies are needed to determine whether patients with HU and SMK history exhibit rapid eGFR deterioration.


  • Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial

    byĀ Kentaro Kohagura, Atsushi Satoh, Masako Kochi, Takuto Nakamura, Ryo Zamami, Takeshi Tana, Kazushi Kinjyo, Ryo Funakoshi, Masanobu Yamazato, Akio Ishida, et al.

    Introduction: Xanthine oxidase (XO) inhibitors may slow down chronic kidney disease (CKD) progression. The comparative effectiveness of the different urate-lowering drugs is unknown. The aim of this study was to determine whether urate-lowering therapy with an XO inhibitor (febuxostat) and that with a uricosuric drug (benzbromarone) are comparable in slowing renal function decline in patients with CKD complicated with hypertension and hyperuricemia. Methods: This study was an open-label randomized parallel-group clinical trial of 95 patients with stage G3 CKD in Japan. The patients had hypertension and hyperuricemia without a history of gout. They were randomized to receive febuxostat (n = 47; febuxostat group) or benzbromarone (n = 48; benzbromarone group) and titrated to reduce their serum urate level to 2) between the febuxostat [āˆ’0.23, 95% confidence interval (CI), āˆ’2.00 to 1.55] and benzbromarone (āˆ’2.18, 95% CI, āˆ’3.84 to āˆ’0.52) groups (difference, 1.95; 95% CI, āˆ’0.48 to 4.38; P = 0.115) nor in the secondary end-points, except for XO activity. Febuxostat significantly reduced XO activity (P = 0.010). There were no significant differences in primary and secondary outcomes between the groups. A decrease in eGFR was significantly less in the febuxostat group than that of the benzbromarone group in the CKDG3a, but not in CKDG3b, in the subgroup analysis. There were no adverse effects specific to either drug. Conclusions: No significant differences were found in the effects of febuxostat and benzbromarone in renal function decline in stage G3 CKD complicated with hyperuricemia and hypertension.


  • Association of blood pressure and hyperuricemia with proteinuria and reduced renal function in the general population

    byĀ Masako Kochi, Kentaro Kohagura, Nanako Oshiro, Ryo Zamami, Kazufumi Nagahama, Koshi Nakamura, Yusuke Ohya

    This study aimed to investigate the effect of hyperuricemia (HU) on the association of systolic blood pressure (SBP) with the prevalence of proteinuria and low estimated glomerular filtration rate (eGFR) in the general population. This cross-sectional study enrolled 24,728 Japanese individuals (11,137 men and 13,591 women) who underwent health checkups in 2010. The prevalence of proteinuria and low eGFR (< 60 mL/min/1.73 m2) among participants classified according to serum uric acid levels and SBP was compared. HU was defined as serum uric acid levels higher than the 75th percentile in male and female participants (> 7.2 and > 5.4 mg/dL, respectively). The odds ratio (OR) for proteinuria increased with elevated SBP. This trend was significantly evident in participants with HU. Moreover, there was an interactive effect of SBP and HU on the prevalence of proteinuria in the male (Pfor interaction = 0.04) and female (Pfor interaction = 0.04) participants. Next, we evaluated the OR for low eGFR (< 60 mL/min/1.73 m2) with and without proteinuria based on the presence of HU. The multivariate analysis revealed that the OR for low eGFR with proteinuria increased with elevated SBP, but that for low eGFR without proteinuria decreased. These trends of OR tended to be prevalent among those with HU. The association between SBP and the prevalence of proteinuria was more pronounced in participants with HU. However, the association between SBP and decreased renal function with and without proteinuria might be different regardless of HU.